Cannabismarketcap

MediPharm Labs Stock Forecast & Price Prediction 2026-2027

Algorithmic price targets and analysis for MEDIF based on fundamentals, valuation multiples, and historical data.

$0.0485+0.00%
Neutral

Price Target Summary

Bear Case
$0.0388
-20.0% from current
Base Case
$0.0534
+10.0% from current
Bull Case
$0.0728
+50.0% from current

Technical Outlook

52-Week Range Analysis

$0.0400$0.0755
Current: $0.0485
Support Level
$0.0435
Resistance Level
$0.0720
From 52W High
-35.8%
From 52W Low
+21.3%

Fundamental Analysis

Revenue Growth Projection

Year 1 Projected
—
Year 2 Projected
—
Year 3 Projected
—

Not available: trailing revenue is not reported in our data.

Valuation vs Peers

Current P/S
N/A
Sector Median P/S
2.5x
Assessment
N/A

Cash Position

Cash on Hand
N/A
Total Debt
N/A

Key Metrics

Current Price$0.0485
Market Cap$18.0M
P/S RatioN/A
Revenue (TTM)N/A
Revenue Growth (YoY)—
Gross MarginN/A
Cash on HandN/A
Total DebtN/A
52W High$0.0755
52W Low$0.0400

Signal Breakdown

Overall Signal: Neutral

    Risk Factors

    • Penny stock status (below $1.00) carries heightened volatility and delisting risk.

    Analyst Summary

    MediPharm Labs (MEDIF) is a licensed cannabis producer (LP) with a market capitalization of $18.0M. Trailing revenue is not reported in our data, so we can't compare its price-to-sales ratio with the sector median. Our algorithmic base-case price target of $0.0534 implies upside of 10.0% from current levels. The overall signal is neutral, with a mixed fundamental picture. Investors should weigh the 1 identified risk factor before making any investment decision.

    Frequently Asked Questions

    What is the price target for MEDIF?+
    Our algorithmic base-case price target for MediPharm Labs (MEDIF) is $0.0534, with a bear case of $0.0388 and a bull case of $0.0728. Because trailing revenue is not reported in our data, these targets are simple bands around the current price rather than revenue-based estimates.
    Is MEDIF a buy right now?+
    Based on our algorithmic analysis, MEDIF currently carries a neutral signal. This is not a buy or sell recommendation — always do your own due diligence.
    What is the revenue forecast for MediPharm Labs?+
    We don't publish a revenue projection for MEDIF yet because trailing revenue is not reported in our data.
    What are the risks of investing in MEDIF?+
    Penny stock status (below $1.00) carries heightened volatility and delisting risk.
    How does MEDIF valuation compare to the cannabis sector?+
    MEDIF has no reported price-to-sales ratio in our data because trailing revenue is not available, so we can't compare it with the cannabis sector median of 2.5x.

    Important Disclaimer

    This is not financial advice. Forecasts are algorithmic projections based on historical data and should not be used as the sole basis for investment decisions. Past performance does not guarantee future results. Cannabis stocks carry significant risk including regulatory, market, and operational risks. Always consult with a qualified financial advisor before making investment decisions. Cannabismarketcap does not recommend buying, selling, or holding any security.

    ← Back to MEDIF OverviewAll Cannabis Stocks